COMMUNIQUÉS West-GlobeNewswire
 
      -   
  Scientific Industries Reports Financial Results for Second Quarter of Fiscal Year 202519/08/2025
-   
  Vivos Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update19/08/2025
-   
  Earth Science Tech, Inc. Board of Directors Approves Reduction of Authorized Common Stock19/08/2025
-   
  Madrigal Receives European Commission Approval for Rezdiffra™ (resmetirom) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis19/08/2025
-   
  Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE)19/08/2025
-   
  Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)19/08/2025
-   
  Ligand to Participate in September Investor Conferences19/08/2025
-   
  Arcutis to Present at Upcoming Investor Conferences19/08/2025
-   
  NMDP Announces Nationwide Celebration and Fundraiser to Help Patients in Need of Life-Saving Cell Therapy19/08/2025
-   
  REPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts19/08/2025
-   
  Epione Beverly Hills Releases Landmark Study Led by Dr. Simon Ourian Confirming Long-Term Effectiveness of Non-Surgical Under-Eye Dark Circle Treatment19/08/2025
-   
  MedX Holdings, Inc. (OTC: MEDH) Med X Holdings Q2 2025 Investor Update: We’re at an Inflection Point19/08/2025
-   
  Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum19/08/2025
-   
  IPSEN - Buy-back programme - Art 5 of MAR - Week 33 - 202519/08/2025
-   
  IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 33 - 202519/08/2025
-   
  TRYVIO™ (aprocitentan) now included in ACC/AHA Clinical Practice Guidelines for the treatment of hypertension19/08/2025
-   
  Life Backup Plan to Be Featured on Business Today with Bill and Giuliana Rancic19/08/2025
-   
  24/7 Market News: LIXTE Biotechnology Spotlight- Revisiting the “Too Much of a Good Thing” Strategy for LB-10019/08/2025
-   
  Conclusion d’un partenariat entre Affidea et Skin Analytics en vue d’améliorer l’aide au dépistage du cancer de la peau en Europe au moyen d’une technologie IA19/08/2025
Pages